Scientists confirm HIV capsid is a good drug target despite resistance

A recent study confirms lenacapavir's effectiveness against HIV and highlights the capsid as a promising drug target despite resistance.
News Medical on MSN

Study reveals previously unknown role for viral protein integrase in HIV's life cycle

The tiny shell protecting the HIV virus resembles a slightly rounded ice cream cone, but there is nothing sweet about it.
GEN

HIV’s Capsid Transports the Viral Genome into the Cell’s Nucleus

In order for HIV to replicate, the viral genome must enter into the cell nucleus and integrate into the host cell chromosome. Previous work suggests that the entry proceeds through nuclear pore ...
GEN

Technique Solves HIV Capsid Structure; Could Serve as Blueprint for Capsid-Targeting Antivirals

Scientists at the Electron Bio-Imaging Centre (eBIC) at Diamond Light Source, in the U.K., have harnessed a new technique, using cryo-electron tomography (cryoET) and subtomogram averaging (STA) to ...
Monthly Prescribing Reference

Sunlenca Tablets

Lenacapavir is a multistage, selective inhibitor of HIV-1 capsid function that directly binds to the interface between capsid protein (p24) subunits in hexamers. Surface plasmon resonance sensorgrams ...
Technology Networks

Structural Role of HIV Integrase Uncovers New Drug Opportunity

Researchers revealed that HIV integrase forms structural filaments within the viral capsid, enabling viral infectivity. The ...